Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Thursday, October 28, 2010

A comprehensive overview of the eight FDA-approved disease-modifying therapies used to slow MS activity (including the newly approved oral therapy, Gilenya), and initial findings on many of the experimental treatments in development for the treatment of MS

Information provided by: Cherie C. Binns RN BS MSCN

From the MS Association of America's Motivator Summer/Fall 2010 issue

Based on the positive response to the "MS Research Updates" published from 2007 through 2009 in New England Journal of Medicine, this year's article incorporates new information about the eight approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the treatment of MS. Highlights and recent study results are provided for each drug. This is not a complete list and not all information is included. Initial findings should be considered as preliminary, as additional studies and/or evaluations may be needed.

CLICK HERE to read this very well written / complete article on what we ( the MS patients), need to know to be kept informed and up-to-date.



***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************



Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Wednesday, October 27, 2010

MS Patients Find Comfort, Flexibility In Yoga

Experts say with the right supervision, exercise can help manage symptoms of multiple sclerosis, and a special Staten Island yoga program could be helping improve outcomes among MS patients. NY1's Health reporter Kafi Drexel filed the following report.
Larissa Nusser and Denise Danton-Nizarre met eight years ago when Nusser attended Danton-Nizarre's first ever yoga class as a student living with multiple sclerosis.
"One of the issues she was having was balancing. Throughout the class, I kept saying to her, 'You can do it, you can do it, you can do it.' And that sort of became our theme," says Danton-Nizzare.
Nusser credits yoga with a dramatic change in her health outlook. So when they co-founded the You Can Do It Yoga Center in Richmond Valley, Staten Island, it seemed a natural fit to offer a special class for students living with MS. They have even created supplemental DVDs.
"I was diagnosed 10 years ago. I was in a wheelchair, actually, when I was diagnosed and I started transforming right in the first yoga class I went to," says Nusser.
Multiple sclerosis or MS, attacks the nervous system. According to the National Multiple Sclerosis Society, about 400,000 Americans are living with the disease and 200 people are newly diagnosed each week. Symptoms can be moderate, with numbness in the limbs. More severe symptoms can include paralysis or vision loss.
Read More and View a video found here


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

MSF Cruise For a Cause® CELEBRATES ITS 10TH YEAR OF CRUISING ABOARD THE OASIS OF THE SEAS




This is a promotion for the MS Foundation's Cruise for a Cause.


The largest and most revolutionary cruise ship in the world. An architectural marvel at sea, spanning 16 decks. Experience the most innovative and imaginative ship yet, Oasis of the Seas - where, for the first time ever, entertainment areas have become neighborhoods at sea.  Find a revolutionary public space combining nature with nautical in the Central Park neighborhood, or old-world charm with a modern twist in the entertaining Boardwalk neighborhood.  Visit the Pool and Sports Zone to explore an entire deck of pools and more.  And don't forget the Youth Zone - where kids can be kids and parents can be worry-free.  With seven distinct onboard neighborhoods, everyone can discover a place for unique experiences.



Now entering its tenth year, the MSF Cruise for a Cause provides an empowering adventure.  Traveling with fellow MS Cruisers, their families, as well as healthcare professionals, and of course, MSF staff, the trip is an unforgettable experience.

With the magnificent sun drenched and exotic Caribbean ports of St Thomas, St. Maarten and Bahamas as our ports of call, the Oasis of the Seas will make our 2011 Cruise for a Cause a dream come true for people with MS.

Some people with MS face unique challenges when traveling.  You may feel that you can no longer travel safely or comfortably. But these hurdles can be overcome, and the MSF Cruise for a Cause is a great place to start. On-board, courteous, and attentive staff caters to your needs.  Fine food, spectacular entertainment, great shopping, and exciting accessible portside activities are available as well.

Save these dates and join us!


September 10 to 17, 2011Cruise Line: Royal Caribbean
Ship: Oasis of the Seas
Destinations: Bahamas,St Thomas and St. Maarten
Departure: Fort Lauderdale FL 5:00 p.m. September 10, 2011.
Day 2: Nassau, Bahamas 7:00 a.m. -2:00 p.m.
Day 3: Cruising
Day 4: Charlotte Amalie, St. Thomas 9:00 a.m.-.5:00 p.m.
Day 5: Philipsburg St. Maarten 7:00 a.m.-5:00 p.m.
Day 6: Cruising
Day 7:  Cruising
Day 8: Arrive Fort Lauderdale.


READ More - including Pricing (per person) and other fees by clicking more



***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Tuesday, October 26, 2010

Early Treatment With Glatiramer Acetate Improved Outcomes in CIS (Clinically Isolated Syndrome)

October 25, 2010
By: SHARON WORCESTER, Internal Medicine News Digital Network



Patients with clinically isolated syndrome who receive early treatment with glatiramer acetate have more than a 40% reduction in the risk of developing multiple sclerosis, compared with those whose treatment is delayed, according to findings from a prospectively planned 5-year follow-up of patient in the phase III PreCISe study.
After a 2-year extension phase of the 3-year double-blind, placebo-controlled study, 33% of 80 patients who had received early treatment with glatiramer acetate (GA) developed clinically definite multiple sclerosis (CDMS), compared with 50% of 118 patients who began treatment at the end of the initial 3-year double-blind phase. Each patient received 20 mg of GA daily by subcutaneous injection.


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis

October 26, 2010

TERACLES is the First Phase III Study of an Oral Drug as an Add-On to Standard Therapy in Relapsing Multiple Sclerosis


PARIS, October 26, 2010 /PRNewswire via COMTEX/ -- Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy.
"Initiation of the TERACLES study is a tremendous milestone as it is the first ever Phase III study of an oral drug in adjunct therapy to be launched in multiple sclerosis," said Marc Cluzel, M.D., Ph.D., Executive Vice President, Research & Development, sanofi-aventis. "We are confident that teriflunomide is an excellent candidate for assessing innovative adjunct therapy in multiple sclerosis considering the positive effect observed when it was used in adjunct with interferon beta in the Phase II study."
Specifically, the TERACLES study will evaluate whether once daily oral teriflunomide 14 or 7mg, in patients treated for at least 6 months on a stable dose of IFN beta prior to randomization, can reduce the annualized relapse rate (primary endpoint) compared to IFN beta plus oral placebo tablets. The main secondary endpoints of the study are to document the disease activity measured by MRI, the time to disability progression and overall safety.

Continue


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Monday, October 25, 2010

Help US to Keep YOUR information Up-to-date, so that you do not miss-out on the MS information we provide

Dear MS Friends, 


We are constantly trying to find ways to improve our services and to stay up-to-date with our members' contact information. 


When there is a change in your email address, please contact us by email to update our records. 


Write to: info@msviewsandnews.org to update our database.



THANK YOU 


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************

DATA FURTHER SUPPORTING ANTI-JC VIRUS ANTIBODY ASSAY PRESENTED AT THE 26TH CONGRESS OF THE European Committee for Treatment and Research in Multiple Sclerosis

 Studies support potential of assay to stratify risk of PML in TYSABRI-treated patients -

Gothenburg, Sweden – October 16, 2010 – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum. The detection of anti-JCV antibodies may provide a means to segment, or stratify, multiple sclerosis (MS) patients considering or receiving treatment with TYSABRI® (natalizumab) and assess their risk for developing progressive multifocal leukoencephalopathy (PML), a rare, but serious, brain infection. These data have been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

This two-step, analytically-validated, enzyme-linked immunosorbant assay (ELISA) to detect anti-JCV antibodies is currently being evaluated in large-scale, prospective clinical studies (>10,000 patients) to determine the utility of the assay in stratifying the risk of PML in TYSABRI-treated patients. Infection with JCV is one of a number of factors required for the development of PML. Detection of anti-JCV antibodies may be a useful tool to identify prior or ongoing JCV infection, helping physicians better assess a patient’s potential risk for developing PML.

“When treating a debilitating, chronic disease such as MS, patient safety is of the utmost importance. At Biogen Idec, we are committed to improving the lives of people with MS. Understanding and mitigating potential treatment risk factors further support our commitment,” said Alfred Sandrock, M.D., Ph.D., Senior Vice President of Neurology Research and Development at Biogen Idec. "We are committed to better understanding PML and have embarked on a number of risk mitigation efforts. The anti-JCV antibody assay is one of our most advanced initiatives and has the potential to provide physicians a tool to help them assess patients’ risk for developing PML." 

***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

National Neurological Diseases Surveillance System Act

Information provided by Cherie C. Binns RN BS MSCN


Late last night, the House of Representatives passed H.R. 1362, the National Neurological Diseases Surveillance System Act—bringing it one significant step closer to becoming law! The bill passed via unrecorded voice vote and will now be await Senate action. This success is due in large part to two years of advocacy efforts by our chapters and grassroots activists.

Background on Expanded Bill:
The legislation will establish a national data surveillance system that will track and collect data on the epidemiology, incidence, prevalence, and other factors of neurological diseases, including MS. This broadened bill was developed in consultation with the Centers for Disease Control (CDC). As technology evolves, the CDC will develop and incorporate new and innovative ways to collect and communicate public health information. In order to build the most nimble system to accommodate changing technology and most efficiently use funding, it was recommended by the CDC that the system not only include MS and Parkinson’s, but also make the system open to all neurological diseases. MS and Parkinson’s are maintained as priorities in the newly expanded legislation. 


READ MORE


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************